Stay updated on Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial
Sign up to get notified when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FqANKtBWehXzMGHXzN9OEOCWYa64.uncropped.jpg&w=3840&q=75)
Latest updates to the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0 and now includes 11 locations, replacing the previous version v2.9.7.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Revision: v2.9.0' has been updated to 'MedlinePlus Genetics related topics: Head and neck squamous cell carcinoma FDA Drug and Device Resources' in the webpage. This change likely indicates an update in the information related to genetics topics and FDA resources for the study on the combination trial of Tipifarnib and Alpelisib in Adult Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.SummaryDifference53%
Stay in the know with updates to Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.